Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226807 · ClinicalTrials.gov registry record · NA
Impact of Earlier Postpartum Contact on Postpartum Visit Compliance and Maternal Wellbeing
A NA study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT04226807: Clinical Trial NA study, sponsored by Montefiore Medical Center.
NCT04226807 is a NA study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04226807, a NA study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The American College of Obstetricians and Gynecologists has recommended a paradigm shift in how postpartum care is instituted. They recommend that in addition to the normal 4-12 week postpartum visit, women receive contact with a provider within the first 3 weeks after giving birth. This RCT will randomize patients to routine care- 6-12 week postpartum visit alone- or enhanced care- routine care plus a phone call within the first 3 weeks postpartum. The patients will then be asked to complete a follow up survey at 6 months postpartum. The primary outcome measure would be rates of compliance with the 6-12 week postpartum visit. Secondary outcome measures will include breastfeeding rates, rates of postpartum depression, hospital readmission rates and met desire for contraception.
Primary Outcome
Percentage of women attending comprehensive postpartum visit
Interventions
- OTHER Early Postpartum Phone Call
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-01-31 |
| Est. Completion | 2022-01-31 |
| Phase | NA |
Why NCT04226807 stopped before completion
NCT04226807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Early Postpartum Phone Call is the first listed.
NCT04226807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04226807 about?
NCT04226807 is a clinical study titled "Impact of Earlier Postpartum Contact on Postpartum Visit Compliance and Maternal Wellbeing". The American College of Obstetricians and Gynecologists has recommended a paradigm shift in how postpartum care is instituted. They recommend that in addition to the normal 4-12 week postpartum visit, women receive contact with a provider within the first 3 weeks after giving birth. This RCT will ra...
What is the current status of trial NCT04226807?
This trial is currently terminated. It is a NA study. The enrollment target is 52 participants. The study started on 2021-01-31. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04226807?
The interventions under investigation include: Early Postpartum Phone Call (OTHER).
Who is sponsoring clinical trial NCT04226807?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04226807's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI